Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Thrombosis Research

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2015.02.034PMID 25795563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Psychosocial and medical determinants of long-term patient outcomes

  2014cited by this paper
• Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo

  2013cited by this paper
• Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity

  2013cited by this paper
• Factor VIIIa A2 Subunit Shows a High Affinity Interaction with Factor IXa

  2013cited by this paper
• A survey of the outcome of prophylaxis, on‐demand treatment or combined treatment in 18–35‐year old men with severe haemophilia in six countries

  2013cited by this paper
• Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.

  2012cited by this paper
• Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications.

  2012cited by this paper
• The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.

  2012cited by this paper
• Haemophilia B: impact on patients and economic burden of disease

  2011cited by this paper
• Interactions between residues 2228–2240 within factor VIIIa C2 domain and factor IXa Gla domain contribute to propagation of clot formation

  2011cited by this paper
• Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency.

  2010cited by this paper
• Generation of a novel factor IX with augmented clotting activities in vitro and in vivo

  2010influential reference
• Monitoring platelet dependent thrombin generation in mice.

  2010cited by this paper
• Factor IX mutants with enhanced catalytic activity

  2009cited by this paper
• X-linked thrombophilia with a mutant factor IX (factor IX Padua).

  2009cited by this paper
• Prophylactic therapy in haemophilia.

  2009cited by this paper
• Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B

  2005cited by this paper
• Preparation of washed platelet suspensions from human and rodent blood.

  2004cited by this paper
• Structure-function relationships in factor IX and factor IXa.

  2003cited by this paper
• Calibrated Automated Thrombin Generation Measurement in Clotting Plasma

  2003cited by this paper
• Identification of Functionally Important Residues of the Epidermal Growth Factor-2 Domain of Factor IX by Alanine-scanning Mutagenesis

  2002cited by this paper
• Expression of Coagulation Factor IX in a Haematopoietic Cell Line

  2002cited by this paper
• The Connecting Segment between Both Epidermal Growth Factor-like Domains in Blood Coagulation Factor IX Contributes to Stimulation by Factor VIIIa and Its Isolated A2 Domain*

  2002cited by this paper
• The Factor IXa Second Epidermal Growth Factor (EGF2) Domain Mediates Platelet Binding and Assembly of the Factor X Activating Complex*

  2002cited by this paper
• Making a therapeutic choice: human versus recombinant fractions – can we do it?

  2001cited by this paper
• Factor IXa:Factor VIIIa Interaction

  2001influential reference
• The carboxyl-terminal region of protein C is essential for its secretion.

  2000cited by this paper
• Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII.

  2000cited by this paper
• The Three In-frame ATG, Clustered in the Translation Initiation Sequence of Human Factor IX Gene, Are Required for an Optimal Protein Production

  1999cited by this paper
• Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity.

  1999cited by this paper
• The Carboxyl-Terminal Region of Protein C Is Essential for Its Secretion

  1998cited by this paper
• Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity*

  1998cited by this paper
• The carboxyl-terminal region of factor IX is essential for its secretion.

  1997influential reference
• A coagulation factor IX-deficient mouse model for human hemophilia B.

  1997cited by this paper
• High-affinity, specific factor IXa binding to platelets is mediated in part by residues 3-11.

  1994cited by this paper
• Molecular basis of vitamin K-dependent gamma-carboxylation.

  1990cited by this paper
• Comparative interactions of factor IX and factor IXa with human platelets.

  1989cited by this paper
• Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.

  1985cited by this paper
• Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential.

  1985cited by this paper
• The role of phospholipid and factor VIIIa in the activation of bovine factor X.

  1981cited by this paper

• In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study.

  2023cites this paper
• The advances of blood clots used as biomaterials in regenerative medicine.

  2022cites this paper
• Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product

  2021cites this paper
• Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product

  2021cites this paper
• Generation of hyperfunctional recombinant human factor IX variants expressed in human cell line SK-Hep-1

  2020influential citation
• Analysis of coagulation factor IX in bioreactor cell culture medium predicts yield and quality of the purified product

  2020cites this paper
• Generation of hyperfunctional recombinant human factor IX variants expressed in human cell line SK-Hep-1

  2020cites this paper
• Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice

  2019cites this paper
• The role of magnetic field in the biopharmaceutical production: Current perspectives

  2019cites this paper
• Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.

  2019cites this paper
• Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

  2018cites this paper
• Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX

  2018cites this paper
• The First Intrinsic Tenase Complex Inhibitor with Serine Protease Structure Offers a New Perspective in Anticoagulant Therapy

  2018cites this paper
• Approaches for recombinant human factor IX production in serum-free suspension cultures

  2016cites this paper
• Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives

  2015influential citation